Datavault AI Announces Closing of the Second Tranche of Scilex Holding Company’s Previously Announced Equity Financing

• Second tranche closing of approximately 1,237.6 Bitcoin follows approval by Datavault AI’s stockholders at annual meeting.
• Scilex Holding Company purchased a pre-funded warrant exercisable for approximately 263.91 million shares of Datavault AI common stock in connection with the closing of this second tranche.
• Both companies ramping up collaboration to deliver growth in 2026.

PHILADELPHIA, Nov. 26, 2025 (GLOBE NEWSWIRE) -- via IBN -- Datavault AI (NASDAQ: DVLT, “Datavault” or the “Company”), a provider of data monetization, credentialing, and real-world asset tokenization technologies, today announces that it has closed the second tranche of its previously announced equity financing with Scilex Holding Company (NASDAQ: SCLX, “Scilex”), issuing to a Scilex pre-funded warrant exercisable for 263,914,094 shares of Datavault common stock in exchange for a purchase of approximately 1,237.6 Bitcoin. The closing of the second tranche of Scilex’s strategic investment followed the approval by the Datavault AI stockholders at its November 24, 2025, annual meeting of, among other things, (1) the issuance of the shares of Datavault common stock upon exercise of the pre-funded warrant and (2) the amendment of Datavault’s certificate of incorporation to increase the number of authorized shares of Datavault common stock. This second tranche of Scilex’s equity investment follows Datavault’s September 26, 2025, closing of the initial tranche, in Bitcoin, valued at approximately $8 million.

Datavault’s strategic transaction with Scilex is designed to provide growth capital to strengthen Datavault’s digital asset reserves, accelerate its supercomputing infrastructure, support ongoing platform expansion, and unlock new revenue streams.

Scilex and Datavault Growing AI Collaboration
As previously announced, Datavault granted Scilex a worldwide exclusive license, with the right to sublicense, for the Company’s proprietary AI-driven technology. This license is tailored for use within the biotech and biopharma industry, enabling Scilex to create and operate a Biotech Exchange platform. 

Under the terms of that licensing agreement, Datavault AI will receive a nonrefundable upfront license fee in four equal installments of $2.5 million each, payable by Scilex on or before December 31, 2025, March 31, 2026, June 30, 2026, and September 30, 2026. Datavault AI is also eligible for sales milestone payments of up to an aggregate of $2.55 billion upon Scilex achieving certain sales milestones.